Proteasome as an emerging therapeutic target in cancer

Current Pharmaceutical Design

Volumn 13, Issue 5, 2007, Pages 471-485

  Zavrski, I ^a   Kleeberg, L ^a   Kaiser, M ^a   Fleissner, C ^a   Heider, U ^a   Sterz, J ^a   Jakob, C ^a   Sezer, O ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bortezomib; Cancer; Inflammation; Lymphoma; Myeloma; Proteasome; PS 519

Indexed keywords

BORONIC ACID DERIVATIVE; BORTEZOMIB; CELL PROTEIN; CISPLATIN; CYCLINE; CYTARABINE; DEXAMETHASONE; DOCETAXEL; DOXORUBICIN; FLAVOPIRIDOL; FLUDARABINE; GEMCITABINE; IDARUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTACYSTIN; LACTACYSTIN BETA LACTONE; MELPHALAN; MG 262; MYC PROTEIN; NPI 0052; PLACEBO; PREDNISONE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BAX; PROTEIN C FOS; PROTEIN C JUN; PROTEIN MDM2; PROTEIN P53; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ABDOMINAL PAIN; ANEMIA; APOPTOSIS; ARTHRALGIA; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL GROWTH; CELL PROLIFERATION; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG IDENTIFICATION; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ELECTROLYTE DISTURBANCE; ENZYME INHIBITION; FATIGUE; FEBRILE NEUTROPENIA; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; GENE ACTIVATION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC TRANSCRIPTION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HUMAN; HYPONATREMIA; ILEUS; IMMUNE RESPONSE; INFECTION; INFLAMMATION; INJECTION SITE DISCOMFORT; LEUKOPENIA; LYMPHOCYTOPENIA; MALAISE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYALGIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; ORTHOSTATIC HYPOTENSION; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN STABILITY; PRURITUS; RESPIRATORY TRACT DISEASE; REVIEW; SENSORY NEUROPATHY; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH PERFORATION; STROKE; STRUCTURE ANALYSIS; SYNCOPE; TASTE DISORDER; THROMBOCYTOPENIA; TRANSCRIPTION REGULATION; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; HUMANS; NEOPLASMS; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX;

EID: 33847365658     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207780162908     Document Type: Review

References (141)

1. Tanaka K, Yoshimura T, Kumatori A, Ichihara A, Ikai A, Nishigai M, et al. Proteasomes (multi-protease complexes) as 20 S ringshaped particles in a variety of eukaryotic cells. J Biol Chem 1988; 263: 16209-17.
2. Arrigo AP, Tanaka K, Goldberg AL, Welch WJ. Identity of the 19S 'prosome' particle with the large multifunctional protease complex of mammalian cells (the proteasome). Nature 1988; 331: 192-4.
3. Adams J. The proteasome: structure, function, and role in 4 the cell. Cancer Treat Rev 2003; 29: 3-9.
4. Ciechanover A, Orian A, Schwartz AL. Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000; 22: 442-51.
5. Elliott PJ, Zollner TM, Boehncke WH. Proteasome inhibition: a new anti-inflammatory strategy. J Mol Med 2003; 81: 235-45.
6. Walz J, Erdmann A, Kania M, Typke D, Koster AJ, Baumeister W. 26S proteasome structure revealed by three-dimensional electron microscopy. J Struct Biol 1998; 121: 19-29.
7. Hough R, Pratt G, Rechsteiner M. Purification of two high molecular weight proteases from rabbit reticulocyte lysate. J Biol Chem 1987; 262: 8303-13.
8. Adams J, Behnke M, Chen S, Cruickshank AA, Dick LR, Grenier L, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett 1998; 8: 333-8.
9. Groll M, Koguchi Y, Huber R, Kohno J. Crystal structure of the 20 S proteasome: TMC-95A complex: a non-covalent proteasome inhibitor. J Mol Biol 2001; 311: 543-8.
10. Hoffman L, Rechsteiner M. Activation of the multicatalytic protease. The 11 S regulator and 20 S ATPase complexes contain distinct 30-kilodalton subunits. J Biol Chem 1994; 269: 16890-5.
11. Braun HA, Umbreen S, Groll M, Kuckelkorn U, Mlynarczuk I, Wigand ME, et al. Tripeptide mimetics inhibit the 20 S proteasome by covalent bonding to the active threonines. J Biol Chem 2005; 280: 28394-401.
12. Stein RL, Melandri F, Dick L. Kinetic characterization of the chymotryptic activity of the 20S proteasome. Biochemistry 1996; 35: 3899-908.
13. Seeger M, Ferrell K, Dubiel W. The 26S proteasome: a dynamic structure. Mol Biol Rep 1997; 24: 83-8.
14. Kumatori A, Tanaka K, Inamura N, Sone S, Ogura T, Matsumoto T, et al. Abnormally high expression of proteasomes in human leukemic cells. Proc Natl Acad Sci USA 1990; 87: 7071-5.
15. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998; 5: 1062-75.
16. Fenteany G, Standaert RF, Lane WS, Choi S, Corey EJ, Schreiber SL. Inhibition of proteasome activities and subunit-specific aminoterminal threonine modification by lactacystin. Science 1995; 268: 726-31.
17. Dick LR, Cruikshank AA, Destree AT, Grenier L, McCormack TA, Melandri FD, et al. Mechanistic studies on the inactivation of the proteasome by lactacystin in cultured cells. J Biol Chem 1997; 272: 182-8.
18. Loidl G, Groll M, Musiol HJ, Huber R, Moroder L. Bivalency as a principle for proteasome inhibition. Proc Natl Acad Sci USA 1999; 96: 5418-22.
19. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615-22.
20. Chauhan D, Catley L, Li G, Podar K, Hideshima T, Velankar M, et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005; 8: 407-19.
21. Macherla VR, Mitchell SS, Manam RR, Reed KA, Chao TH, Nicholson B, et al. Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor. J Med Chem 2005; 48: 3684-7.
22. Corey EJ, Li WD. Total synthesis and biological activity of lactacystin, omuralide and analogs. Chem Pharm Bull 1999; 47: 1-10.
23. Shah IM, Lees KR, Pien CP, Elliott PJ. Early clinical experience with the novel proteasome inhibitor PS-519. Br J Clin Pharmacol 2002; 54: 269-76.
24. Hershko A. Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 1997; 9: 788-99.
25. Turnell AS, Stewart GS, Grand RJ, Rookes SM, Martin A, Yamano H, et al. The APC/C and CBP/p300 cooperate to regulate transcription and cell-cycle progression. Nature 2005; 438: 690-5.
26. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
27. Chang YC, Lee YS, Tejima T, Tanaka K, Omura S, Heintz NH, et al. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ 1998; 9: 79-84.
28. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science 1998; 281: 1322-6.
29. Blagosklonny MV, Wu GS, Omura S, el-Deiry WS. Proteasome-dependent regulation of p21WAF1/CIP1 expression. Biochem Biophys Res Commun 1996; 227: 564-9.
30. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, et al. Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 1995; 269: 682-5.
31. Scheffner M, Huibregtse JM, Vierstra RD, Howley PM. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993; 75: 495-505.
32. Chowdary DR, Dermody JJ, Jha KK, Ozer HL. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol Cell Biol 1994; 14: 1997-2003.
33. Maki CG, Huibregtse JM, Howley PM. In vivo ubiquitination and proteasome-mediated degradation of p53(1). Cancer Res 1996; 56: 2649-54.
34. Pahl HL. Activators and target genes of Re1/NF-kappaB transcription factors. Oncogene 1999; 18: 6853-66.
35. Rodriguez MS, Wright J, Thompson J, Thomas D, Baleux F, Virelizier JL, et al. Identification of lysine residues required for signal-induced ubiquitination and degradation of I kappa B-alpha in vivo. Oncogene 1996; 12: 2425-35.
36. He H, Qi XM, Grossmann J, Distelhorst CW. c-Fos degradation by the proteasome. An early, Bcl-2-regulated step in apoptosis. J Biol Chem 1998; 273: 25015-9.
37. Stancovski I, Gonen H, Orian A, Schwartz AL, Ciechanover A. Degradation of the proto-oncogene product c-Fos by the ubiquitin proteolytic system in vivo and in vitro: identification and characterization of the conjugating enzymes. Mol Cell Biol 1995; 15: 7106-16.
38. Jariel-Encontre I, Pariat M, Martin F, Carillo S, Salvat C, Piechaczyk M. Ubiquitinylation is not an absolute requirement for degradation of c-Jun protein by the 26 S proteasome. J Biol Chem 1995; 270: 11623-7.
39. Nakayama K, Furusu A, Xu Q, Konta T, Kitamura M. Unexpected transcriptional induction of monocyte chemoattractant protein 1 by proteasome inhibition: involvement of the c-Jun N-terminal kinase-activator protein 1 pathway. J Immunol 2001; 167: 1145-50.
40. Hideshima T, Mitsiades C, Akiyama M, Hayashi T, Chauhan D, Richardson P, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003; 101: 1530-4.
41. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-80.
42. Adams J. The proteasome: a suitable antineoplastic target. Nat Rev Cancer 2004; 4: 349-60.
43. Hideshima T, Richardson P, Chauhan D, Palombella VJ, Elliott PJ, Adams J, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-6.
44. Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med 1999;5: 412-7.
45. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Fanourakis G, Gu X, et al. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci USA 2002; 99: 14374-9.
46. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101: 2377-80.
47. Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-44.
48. David E, Sun SY, Waller EK, Chen J, Khuri FR, Lonial S. The combination of the farnesy1 transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of pAKT. Blood 2005; 106: 4322-9.
49. Heider U, Kaiser M, Sterz J, Zavrski I, Jakob C, Fleissner C, et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 2006; 76: 42-50.
50. Kaiser M, Zavrski I, Sterz J, Jakob C, Fleissner C, Kloetzel PM, et al. The histone deacetylase inhibitor valproic acid induces cell cycle arrest, growth suppression and apoptosis in multiple myeloma. Haematologica 2006; 91: 248-51.
51. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res 2004; 10: 3839-52.
52. Fahy BN, Schlieman MG, Virudachalam S, Bold RJ. Schedule-dependent molecular effects of the proteasome inhibitor bortezomib and gemcitabine in pancreatic cancer. J Surg Res 2003; 113: 88-95.
53. Desai SD, Liu LF, Vazquez-Abad D, D'Arpa P. Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin. J Biol Chem 1997; 272: 24159-64.
54. Cusack JC Jr, Liu R, Houston M, Abendroth K, Elliott PJ, Adams J, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibition. Cancer Res 2001; 61: 3535-40.
55. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-6.
56. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341: 1565-71.
57. Oikawa T, Sasaki T, Nakamura M, Shimamura M, Tanahashi N, Omura S, et al. The proteasome is involved in angiogenesis. Biochem Biophys Res Commun 1998; 246: 243-8.
58. Sunwoo JB, Chen Z, Dong G, Yeh N, Crowl Bancroft C, Sausville E, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-kappa B, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001; 7: 1419-28.
59. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, et al. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res 2002; 62: 4996-5000.
60. Sezer O, Heider U, Zavrski I, Kuhne CA, Hofbauer LC. RANK ligand and osteoprotegerin in myeloma bone disease. Blood 2003; 101: 2094-8.
61. Heider U, Hofbauer LC, Zavrski I, Kaiser M, Jakob C, Sezer O. Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease. Biochem Biophys Res Commun 2005; 338: 687-93.
62. Abe M, Hiura K, Wilde J, Shioyasono A, Moriyama K, Hashimoto T, et al. Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 2004; 104: 2484-91.
63. Choi SJ, Cruz JC, Craig F, Chung H, Devlin RD, Roodman GD, et al. Macrophage inflammatory protein 1-alpha is a potential osteoclast stimulatory factor in multiple myeloma. Blood 2000; 96: 671-5.
64. Heider U, Langelotz C, Jakob C, Zavrski I, Fleissner C, Eucker J, et al. Expression of receptor activator of nuclear factor kappaB ligand on bone marrow plasma cells correlates with osteolytic bone disease in patients with multiple myeloma Clin Cancer Res 2003; 9: 1436-40.
65. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 2003; 423: 337-42.
66. Zavrski I, Naujokat C, Niemoller K, Jakob C, Heider U, Langelotz C, et al. Proteasome inhibitors induce growth inhibition and apoptosis in myeloma cell lines and in human bone marrow myeloma cells irrespective of chromosome 13 deletion. J Cancer Res Clin Oncol 2003; 129: 383-91.
67. Zangari M, Esseltine D, Lee CK, Barlogie B, Elice F, Burns MJ, et al. Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma. Br J Haematol 2005; 131: 71-3.
68. Heider U, Kaiser M, Müller C, Schulz CO, Jakob C, Zavrski I, et al. Treatment of bortezomib increases osteoblast function in patients with multiple myeloma. Blood 2005; 106(Suppl): 965a (#3457).
69. Naujokat C, Sezer O, Zinke H, Leclere A, Hauptmann S, Possinger K. Proteasome inhibitors induced caspase-dependent apoptosis and accumulation of p21WAF1/Cip1 in human immature leukemic cells. Eur J Haematol 2000; 65: 221-36.
70. Guzman ML, Neering SJ, Upchurch D, Grimes B, Howard DS, Rizzieri DA, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. Blood 2001; 98: 2301-7.
71. Zavrski I, Krebbel H, Wildemann B, Heider U, Kaiser M, Possinger K, et al. Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function. Biochem Biophys Res Commun 2005; 333: 200-5.
72. Tan C, Waldmann TA. Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res 2002; 62: 1083-6.
73. Dai Y, Rahmani M, Pei XY, Dent P, Grant S. Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood 2004; 104: 509-18.
74. Chiarle R, Budel LM, Skolnik J, Frizzera G, Chilosi M, Corato A, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood 2000; 95: 619-26.
75. Pham LV, Tamayo AT, Yoshimura LC, Lo P, Ford RJ. Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 2003; 171: 88-95.
76. Izban KF, Ergin M, Huang Q, Qin JZ, Martinez RL, Schnitzer B, et al. Characterization of NF-kappaB expression in Hodgkin's disease: inhibition of constitutively expressed NF-kappaB results in spontaneous caspase-independent apoptosis in Hodgkin and Reed-Sternberg cells. Mod Pathol 2001; 14: 297-310.
77. Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB, et al. Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 2004; 10: 3207-15.
78. Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, et al. Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002; 20: 4420-7.
79. Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003; 348: 2609-17.
80. Jagannath S, Barlogie B, Berenson J, Siegel D, Irwin D, Richardson PG, et al. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004; 127: 165-72.
81. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or highdose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-98.
82. Jagannath S, Durie BG, Wolf J, Camacho E, Irwin D, Lutzky J, et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005; 129: 776-83.
83. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005; 129: 755-62.
84. Mateos MV, Hernández M, Díaz Mediavilla J, Palomera L, Moro MJ, Hernández J, et al. A Phase I/II National, Multi-Center, Open-Label Study of Bortezomib Plus Melphalan and Prednisone (VMP) in Elderly Untreated Multiple Myeloma (MM) Patients. Blood 2005; 106(Suppl): 232a (#786).
85. Cortes J, Thomas D, Koller C, Giles F, Estey E, Faderl S, et al. Phase I study of bortezomib in refractory or relapsed acute leukemias. Clin Cancer Res 2004; 10: 3371-6.
86. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, Hagemeister F, et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 667-75.
87. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, Stubblefield M, et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005; 23: 676-84.
88. Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105: 3058-65.
89. Koc ON, Bahlis NJ, Liu L, Lazarus HM, Cooper BW, Gerson SL, et al. A phase I trial of bortezomib in combination with fludarabine in patients with lymphoproliferative neoplasms. J Clin Oncol 2005; 23(Suppl 16S): 596s (#6647).
90. Teicher BA, Ara G, Herbst R, Palombella VJ, Adams J. The proteasome inhibitor PS-341 in cancer therapy. Clin Cancer Res 1999; 5: 2638-45.
91. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T, et al. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000; 6: 916-23.
92. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. Clin Cancer Res 2000; 6: 3719-28.
93. Kitagawa H, Tani E, Ikemoto H, Ozaki I, Nakano A, Omura S. Proteasome inhibitors induce mitochondria-independent apoptosis in human glioma cells. FEBS Lett 1999; 443: 181-6.
94. Aghajanian C, Soignet S, Dizon DS, Pien CS, Adams J, Elliott PJ, et al. A phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Clin Cancer Res 2002; 8: 2505-11.
95. Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, et al. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J Clin Oncol 2004; 22: 2108-21.
96. Shah MH, Young D, Kindler HL, Webb I, Kleiber B, Wright J, et al. Phase II study of the proteasome inhibitor bortezomib (PS-341) in patients with metastatic neuroendocrine tumors. Clin Cancer Res 2004; 10: 6111-8.
97. Davis NB, Taber DA, Ansari RH, Ryan CW, George C, Vokes EE, et al. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. J Clin Oncol 2004; 22: 115-9.
98. Kondagunta GV, Drucker B, Schwartz L, Bacik J, Marion S, Russo P, et al. Phase II trial of bortezomib for patients with advanced renal cell carcinoma. J Clin Oncol 2004; 22: 3720-5.
99. Maki RG, Kraft AS, Scheu K, Yamada J, Wadler S, Antonescu CR, et al. A multicenter Phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 2005; 103: 1431-8.
100. Voortman J, Smit E, Kuenen B, Pinedo H, van Groeningen C, van den Eertwegh A, et al. A phase 1B, open-label, dose-escalation study of bortezomib in combination with gemcitabine (Gem) and cisplatin (Cis) in the first-line treatment of patients with advanced solid tumors: preliminary results of a phase IB study. J Clin Oncol 2005; 23(Suppl 16S): 160s (#2103).
101. Dragovich T, Lenz HJ, Rocha Lima CMS, Kozuch P, Hochster H, O'Neil B, et al. Bortezomib ± irinotecan in relapsed/refractory colorectal cancer: Interim analysis results from phase 2b study. Proc Am Soc Clin Oncol 2004; 23: 268 (#3591).
102. Brown J, Von Roenn J, O'Regan R, Bergan R, Badve S, Rademaker A, et al. A phase II study of the proteasome inhibitor PS-341 in patients with metastatic breast cancer. Proc Am Soc Clin Oncol 2004; 23: 13 (#546).
103. Ocean AJ, Schnoll-Sussman F, Chen X, Holloway S, Wright J, Wadler S. Phase II study of PS-341 (VELCADE, bortezomib) with or without irinotecan in patients (pts) with advanced gastric adeno-carcinomas (AGA). Gastrointestinal Cancers Symposium, 2005; abstract 31.
104. Michaelis M, Fichtner I, Behrens D, Haider W, Rothweiler F, Mack A, et al. Anti-cancer effects of bortezomib against chemoresistant neuroblastoma cell lines in vitro and in vivo. Int J Oncol 2006; 28: 439-46.
105. Horton TM, Gannavarapu A, Blaney SM, D'Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol 2006; 58: 13-23.
106. Blaney SM, Bernstein M, Neville K, Ginsberg J, Kitchen B, Horton T, et al. Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015). J Clin Oncol 2004; 22: 4804-9.
107. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16: 225-60.
108. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, et al. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci USA 2004; 101: 8120-5.
109. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, et al. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 2002; 105: 483-9.
110. Phillips JB, Williams AJ, Adams J, Elliott PJ, Tortella FC. Proteasome inhibitor PS519 reduces infarction and attenuates leukocyte infiltration in a rat model of focal cerebral ischemia. Stroke 2000; 31: 1686-93.
111. Palombella VJ, Conner EM, Fuseler JW, Destree A, Davis JM, Laroux FS, et al. Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998; 95: 15671-6.
112. Elliott PJ, Pien CS, McCormack TA, Chapman ID, Adams J. Proteasome inhibition: A novel mechanism to combat asthma. J Allergy Clin Immunol 1999; 104: 294-300.
113. Vanderlugt CL, Rahbe SM, Elliott PJ, Dal Canto MC, Miller SD. Treatment of established relapsing experimental autoimmune encephalomyelitis with the proteasome inhibitor PS-519. J Autoimmun 2000; 14: 205-11.
114. Zollner TM, Podda M, Pien C, Elliott PJ, Kaufmann R, Boehncke WH. Proteasome inhibition reduces superantigen-mediated T cell activation and the severity of psoriasis in a SCID-hu model. J Clin Invest 2002; 109: 671-9.
115. Conner EM, Brand S, Davis JM, Laroux FS, Palombella VJ, Fuseler JW, et al. Proteasome inhibition attenuates nitric oxide synthase expression, VCAM-1 transcription and the development of chronic colitis. J Pharmacol Exp Ther 1997; 282: 1615-22.
116. Hoffman EK, Wilcox HM, Scott RW, Siman R. Proteasome inhibition enhances the stability of mouse Cu/Zn superoxide dismutase with mutations linked to familial amyotrophic lateral sclerosis. J Neurol Sci 1996, 139: 15-20.
117. Feist E, Dorner T, Kuckelkorn U, Schmidtke G, Micheel B, Hiepe F, et al. Proteasome alpha-type subunit C9 is a primary target of autoantibodies in sera of patients with inyositis and systemic lupus erythematosus. J Exp Med 1996; 184: 1313-8.
118. Sudakin V, Ganoth D, Dahan A, Heller H, Hershko J, Luca FC, et al. The cyclosome, a large complex containing cyclin-selective ubiquitin ligase activity, targets cyclins for destruction at the end of mitosis. Mol Biol Cell 1995; 6: 185-97.
119. Zhang Y, Wang Z, Liu DX, Pagano M, Ravid K. Ubiquitin-dependent degradation of cyclin B is accelerated in polyploid megakaryocytes. J Biol Chem 1998; 273: 1387-92.
120. Cooper KF, Mallory MJ, Strich R. Oxidative stress-induced destruction of the yeast C-type cychn Ume3p requires phosphatidylinositol-specific phospholipase C and the 26S proteasome. Mol Cell Biol 1999; 19: 333848.
121. Diehl JA, Zindy F, Sherr CJ. Inhibition of cyclin D1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasgme pathway. Genes Dev 1997; 11: 957-72.
122. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes Dev 1996; 10: 1979-90.
123. Thullberg M, Bartek J, Lukas J. Ubiquitin/proteasome-mediated degradation ofpl9lNK4d determines its periodic expression during the cell cycle. Oncogene 2000; 19: 2870-6.
124. Urano T, Yashiroda H, Muraoka M, Tanaka K, Hosoi T, Inoue S, et al. p57(Kip2) is degraded through the proteasome in osteoblasts stimulated to proliferation by transforming growth factor betal. J Biol Chem 1999; 274: 12197-200.
125. Kho CJ, Huggins GS, Endege WO, Hsieh CM, Lee ME, Haber E. Degradation of E2A proteins through a ubiquifin-conjugating enzyme, UbcE2A. J Biol Chem 1997; 272: 3845-51.
126. Campanero MR, Flemington EK. Regulation of E2F through ubiquitin-proteasome-dependent degradation: stabilization by the pRB tumor suppressor protein. Proc Nad Acad Sci USA 1997; 94: 2221-6.
127. Kim TK, Maniatis T. Regulation of interferon-gamma-activated STAT1 by the ubiquitin-proteasome pathway. Science 1996; 273: 1717-9.
128. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994; 78: 773-85.
129. Traenckner EB, Wilk S, Baeuerle PA. A proteasome inhibitor prevents activation of NF-kappa B and stabilizes a newly phosphorylated form of I kappa B-alpha that is still bound to NF-kappa B. EMBO J 1994; 13: 5433-41.
130. Boyer SN, Wazer DE, Band V. E7 protein of human papilloma virus- 16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Res 1996; 56: 4620-4.
131. Nakajima T, Morita K, Ohi N, Arai T, Nozaki N, Kikuchi A, et al. Degradation of topoisomerase l1alpha during adenovirus E1A-induced apoptosis is mediated by the activation of the ubiquitin proteolysis system. J Biol Chem 1996; 271: 24842-9.
132. Chang YC, Lee YS, Tejima T, Tanaka K, Omura S, Heintz NH, et al. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway. Cell Growth Differ 1998; 9: 79-84.
133. Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in protcasomes in response to apoptotic stimuli. Science 2000; 288: 874-7.
134. Aghajanian C, Dizon DS, Sabbatini P, Raizer JJ, Dupont J, Spriggs DR. Phase I trial of bortezomib and carboplatin in recurrent ovarian or primary peritoneal cancer. J Clin Oncol 2005; 23: 5943-9.
135. Mackay H, Hedley D, Major P, Townsley C, Mackenzie M, Vincent M, et al. A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11: 5526-33.
136. Markovic SN, Geyer SM, Dawkins F, Sharfinan W, Albertim M, Maples W, et al. A phase 11 study of bortezormb in the treatment of metastatic malignant melanoma. Cancer 2005; 103: 2584-9.
137. Fanucchi MP, Fossella F, Fidias P, Natale RB, Belt RJ, Carbone DP, et al. Bortezomib ± docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC): a phase 2 study. J Clin Oncol 2005; 23(Suppl 16S): 629s (#7034).
138. Attar EC, De Angelo DJ, Sirulnik A, Wadleigh M, Ballen KK, Miller KB, et al. Addition of Bortezomib (Velcade) to AML Induction Chemotherapy Is Well Tolerated and Results in a High Complete Remission Rate. Blood 2005; 106(Suppl): 780a (#2782).
139. Moehler TM, Hillengass J, Goldschmidt H, Ho AD. Antiangiogenic therapy in hematologic malignancies. Curr Pharm Des 2004, 10(11):1221-34.
140. Upadhya SC, Hegde AN. Ubiquitin-proteasome pathway components as therapeutic targets for CNS maladies. Curr Pharm Des 2005; 11(29): 3807-28.
141. Yasui K, Kobayashi N, Yamazaki T, Agematsu K. Thalidomide as an immunotherapeutic agent: the effects on neutrophil-mediated inflammation. Curr Pharm Des 2005; 11(3):395-401.